

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

- 1 (currently amended): A ~~medicament for treating neoplasms~~ composition comprising a physiologically acceptable combination of:
 - at least one inhibitor of the effect of a substance negatively effecting an immune response, wherein the inhibitor is an oligonucleotide having a sequence according to one of SEQ ID NOS: 1-213, unmodified or having one or more modifications selected from the group consisting of phosphorothioate internucleotide linkages, methylphosphonate internucleotide linkages, phosphoramidate linkages, peptide linkages, 2'-O-modified sugar, and modified bases and
 - at least one stimulator positively effecting an immune response.
- 2 (currently amended): The ~~medicament~~ composition of claim 1 wherein the inhibitor is inhibiting the synthesis or function of molecules suppressing or downregulating or negatively affecting the immune response.

Claims 3-5 (cancelled).

6 (withdrawn): The ~~medicament~~ composition according to claim 1, wherein the inhibitor is a Fab-fragment or single chain antibody (scFv).

7 (currently amended): The ~~medicament~~ composition according to claim 1, wherein the stimulator is enhancing the synthesis or function of molecules stimulating, enhancing, upregulating and/or positively regulating the immune response.

8 (currently amended): The ~~medicament~~ composition according to claim 7, wherein the stimulator is stimulating and/or enhancing the synthesis and/or the function of factors selected from the group consisting of GM-CSF, SCF, CSF, IFN, FLT-3-ligand, monocyte chemotactic proteins (MCP-1), interleukin-2, interleukin-4, interleukin-12 and/or interleukin-18 or the stimulator is one of the mentioned ~~interlukins~~ interleukins or is selected from the groups consisting of viruses, viral antigens, antigens expressed in tumor cells or pathogens, but not in normal cells, organ specific antigens expressed in affected organs which are not essential for the organism or fusion cell of dendritic and tumor cells.

9 (currently amended): The ~~medicament~~ composition according to claim 1, wherein the ~~medicament~~ composition comprises two or more of the inhibitors and/or the stimulators.

10 (currently amended): An oligonucleotide having a sequence according to one of SEQ ID NOS:

1-213, excluding SEQ ID NOS: 1, 4, 5, 9, 11-13, 15-18, 20, 22, 23, and 25-27, unmodified or having one or modifications selected from the group consisting of phosphorothioate internucleotide linkages, methylphosphonate internucleotide linkages, phosphoramidate linkages, peptide linkages, 2'-O-modified sugar, and modified bases.

11 (previously presented): The oligonucleotide according to claim 10 wherein each oligonucleotide is effective against expression of at least two of TGF- β_1 , TGF- β_2 and/or TGF- β_3 .

Claims 12 and 13 (cancelled).